Lack of interaction between cimetidine and buspirone. 1987

R E Gammans, and M Pfeffer, and M L Westrick, and H C Faulkner, and K D Rehm, and P J Goodson

Simultaneous administration of cimetidine and many benzodiazepine anxiolytics has resulted in decreased body clearance and marked prolongation of the half-life of these agents. The pharmacokinetic interaction of buspirone, a new nonbenzodiazepine anxiolytic, and cimetidine was studied in 10 healthy male volunteers. Each received, in order, buspirone 45 mg/day (days 1-7), no drug (days 8-14), cimetidine 1 g/day (days 15-21), buspirone 45 mg/day plus cimetidine 1 g/day (days 22-28), and cimetidine 1 g/day (days 29-31). Buspirone and 1-pyrimidinyl piperazine (1-PP), an active metabolite, pharmacokinetics, urinary excretion of cimetidine, a manual dexterity test, the Stroop color-word interference test, and a visual analog mood scale were evaluated on each treatment. There were no significant (p greater than 0.05) differences among treatments for any measurement except for a slight (31%) but significant (p less than 0.05) increase in the 1-PP Cmax value. These results suggest that within the normal therapeutic dosage ranges for both drugs, it is unlikely that a clinically significant interaction between them will occur.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D011597 Psychomotor Performance The coordination of a sensory or ideational (cognitive) process and a motor activity. Perceptual Motor Performance,Sensory Motor Performance,Visual Motor Coordination,Coordination, Visual Motor,Coordinations, Visual Motor,Motor Coordination, Visual,Motor Coordinations, Visual,Motor Performance, Perceptual,Motor Performance, Sensory,Motor Performances, Perceptual,Motor Performances, Sensory,Perceptual Motor Performances,Performance, Perceptual Motor,Performance, Psychomotor,Performance, Sensory Motor,Performances, Perceptual Motor,Performances, Psychomotor,Performances, Sensory Motor,Psychomotor Performances,Sensory Motor Performances,Visual Motor Coordinations
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D002065 Buspirone An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM. Anxut,Apo-Buspirone,Bespar,Busp,Buspar,Buspirone Hydrochloride,Gen-Buspirone,Lin-Buspirone,MJ-9022-1,N-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-1-cyclopentanediacetamide,Neurosine,Novo-Buspirone,Nu-Buspirone,PMS-Buspirone,Ratio-Buspirone,Apo Buspirone,Gen Buspirone,Hydrochloride, Buspirone,Lin Buspirone,MJ 9022 1,MJ90221,Novo Buspirone,Nu Buspirone,PMS Buspirone,Ratio Buspirone
D002927 Cimetidine A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output. Altramet,Biomet,Biomet400,Cimetidine HCl,Cimetidine Hydrochloride,Eureceptor,Histodil,N-Cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)guanidine,SK&F-92334,SKF-92334,Tagamet,HCl, Cimetidine,Hydrochloride, Cimetidine,SK&F 92334,SK&F92334,SKF 92334,SKF92334
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

R E Gammans, and M Pfeffer, and M L Westrick, and H C Faulkner, and K D Rehm, and P J Goodson
October 1983, Acta neurologica Scandinavica,
R E Gammans, and M Pfeffer, and M L Westrick, and H C Faulkner, and K D Rehm, and P J Goodson
September 1985, Clinical pharmacology and therapeutics,
R E Gammans, and M Pfeffer, and M L Westrick, and H C Faulkner, and K D Rehm, and P J Goodson
September 1985, Clinical pharmacology and therapeutics,
R E Gammans, and M Pfeffer, and M L Westrick, and H C Faulkner, and K D Rehm, and P J Goodson
February 1994, Pharmaceutical research,
R E Gammans, and M Pfeffer, and M L Westrick, and H C Faulkner, and K D Rehm, and P J Goodson
October 1996, British journal of clinical pharmacology,
R E Gammans, and M Pfeffer, and M L Westrick, and H C Faulkner, and K D Rehm, and P J Goodson
October 1996, Journal of clinical pharmacology,
R E Gammans, and M Pfeffer, and M L Westrick, and H C Faulkner, and K D Rehm, and P J Goodson
January 1988, International journal of clinical pharmacology research,
R E Gammans, and M Pfeffer, and M L Westrick, and H C Faulkner, and K D Rehm, and P J Goodson
March 1993, British journal of rheumatology,
R E Gammans, and M Pfeffer, and M L Westrick, and H C Faulkner, and K D Rehm, and P J Goodson
November 1990, Canadian journal of psychiatry. Revue canadienne de psychiatrie,
R E Gammans, and M Pfeffer, and M L Westrick, and H C Faulkner, and K D Rehm, and P J Goodson
November 1987, Anesthesia and analgesia,
Copied contents to your clipboard!